Key result
MRA therapy withdrawal occurs in ~49% of incident heart failure patients within five years.
Why the study?
Despite landmark HFrEF trials demonstrating benefits of MRAs, it has been suggested that MRAs are underutilized or frequently withdrawn.
Population
51 512 patients with incident HF in Denmark from 2003-2017
Comparison
MRA initiation and subsequent withdrawal or adherence over time
Design
Nationwide registry-based cohort study
Follow-up
5 years
Authors
Loading...
Frequent real-world MRA withdrawal in HF warrants caution on long-term use; leaves open prospective trials on retention strategies.
Cohort (n=51,512)
Yes
In a real-world nationwide cohort, MRA therapy is underutilized and frequently withdrawn in heart failure patients, highlighting a need for improved retention strategies.
Zahir et al. (2021) conducted a cohort in Heart failure (n=51,512). Mineralocorticoid receptor antagonists (MRA) was evaluated on Incidence of withdrawal of MRA. Among incident heart failure patients initiating MRA therapy, the incidence of withdrawal was 49.2% within 5 years, with only 48.0% remaining adherent to the treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: